Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Solvay Pharmaceuticals |
---|---|
Information provided by: | Solvay Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00160134 |
The study is a randomized, placebo controlled, multi-center, single dose study to evaluate cardiac hemodynamics and safety of iv SLV320 in 110 subjects with congestive heart failure requiring diuretic treatment. Each subject will receive one dose of SLV320 or placebo or furosemide. The study consists of three visits (or study days when in-subjects are included). Ambulatory subjects will be in hospital for two nights and one day.
Condition | Intervention | Phase |
---|---|---|
Congestive Heart Failure |
Drug: SLV320 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Parallel Group, Single Dose Study to Evaluate Cardiac Hemodynamics and Safety During Right Heart Catheterization of Three IV Doses of SLV320 in Subjects With Congestive Heart Failure Requiring Diuretic Treatment |
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | S320.2.002, 2004-000442-21 |
Study First Received: | September 8, 2005 |
Last Updated: | July 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00160134 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; Serbia and Montenegro: Agency for Drugs and Medicinal Devices; Norway: Norwegian Medicines Agency |
congestive heart failure, adenosine receptor blocker, cardiac hemodynamic |
Heart Failure Heart Diseases Adenosine |
Cardiovascular Diseases |